STOCK TITAN

IO Biotech, Inc. - IOBT STOCK NEWS

Welcome to our dedicated page for IO Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on IO Biotech stock.

IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company dedicated to developing innovative immune therapies for treating cancer. Their focus is on creating first-in-class immune-modulating anti-cancer treatments based on a groundbreaking platform technology. This platform enables the activation of T cells that specifically target immune inhibitory molecules.

IO Biotech has a robust pipeline featuring two leading immune-modulating therapies, IDO and PD-L1, which are currently in clinical development. Additionally, several other compounds are nearing the end of the preclinical phase. The company's proven track record in advancing compounds to the clinical stage underscores their expertise and commitment to innovation in cancer treatment.

The company's product candidates utilize the T-win technology platform, designed to trigger the immune system to attack and disrupt multiple pathways that regulate tumor-induced immunosuppression. This unique approach aims to enhance the body's natural ability to fight cancer, offering a promising avenue for patients battling this disease.

With an experienced management team and a world-class advisory board, IO Biotech is well-positioned in the field of immuno-oncology. Recent achievements include the advancement of their pivotal Phase 3 Clinical Trial (IOB-013/KN-D18) and significant progress with their drugs IO102 and IO103. The company’s dedication to cutting-edge research and development is evident through their continuous efforts in preclinical and clinical trials.

For the latest updates and detailed information about IO Biotech, their therapies, ongoing projects, and financial condition, visit their official website or contact Maryann Cimino, Director of Investor Relations, at mci@iobiotech.com.

Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced two poster presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas on November 8-10, 2024. The first poster will present updated data from the complete cohort (n=31) of PD-L1 high metastatic non-small cell lung cancer (NSCLC) patients in the Phase 2 basket trial of IO102-IO103 combined with pembrolizumab. The second poster will showcase new pre-clinical data for IO112, targeting Arginase 1. Dr. Jonathan W. Riess from UC Davis will present the NSCLC data, while IO Biotech scientists will present the IO112 data. Both posters will be displayed on November 9, 2024, at the George R. Brown Convention Center and will be available on IO Biotech's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.86%
Tags
none
-
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced positive results from its Phase 2 trial of IO102-IO103, a therapeutic cancer vaccine, in combination with Merck's KEYTRUDA® for advanced head and neck cancer. The study met its primary endpoint with a 44.4% overall response rate in PD-L1 high patients. Key findings include:

- 6.6-month median progression-free survival
- 66.7% disease control rate
- Safety profile consistent with previous data
- T-cell responses detected for both IO102 and IO103

The trial enrolled patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 CPS ≥ 20. These results support further investigation of the combination as a potential first-line treatment for metastatic and difficult-to-treat cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of its pivotal Phase 3 trial for IO102-IO103, a novel therapeutic cancer vaccine, in combination with KEYTRUDA® (pembrolizumab) for advanced melanoma. Key points:

1. No new safety signals observed
2. Primary endpoint of progression-free survival (PFS) projected for first half of 2025
3. Trial powered at 89% to detect a 35% reduction in event risk
4. 407 patients randomized
5. Interim analysis did not meet criteria for superiority in overall response rate (ORR)
6. Company remains optimistic based on Phase 1/2 results showing 25.5 months median PFS

IO Biotech also reported promising preliminary data from a Phase 2 basket trial in NSCLC and SCCHN, with upcoming presentations at medical conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's senior management will provide corporate updates and engage in one-on-one meetings at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 4, 2024. CEO Mai-Britt Zocca, PhD, will participate in a fireside chat at 5:35 pm ET.

2. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024. CFO Amy Sullivan will present at 10:30 am ET.

Webcasts of both presentations will be available on IO Biotech's website for 90 days following the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences
-
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) reported Q2 2024 financial results and business highlights. Key points include:

1. Phase 3 interim analysis for IO102-IO103 in advanced melanoma expected in Q3 2024.
2. Completed enrollment in Phase 2 trials for NSCLC and SCCHN.
3. Data from SCCHN cohort accepted for ESMO 2024 presentation.
4. Ended Q2 with $100.7 million in cash, expected to support operations into Q4 2025.
5. Net loss of $20.7 million for Q2 2024, compared to $21.2 million in Q2 2023.
6. R&D expenses decreased to $15.8 million from $16.5 million year-over-year.
7. G&A expenses increased to $5.7 million from $5.3 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced that an abstract on their lead therapeutic cancer vaccine candidate, IO102-IO103, has been accepted for poster presentation at the ESMO Congress 2024. The presentation will showcase data from a completed cohort of squamous cell carcinoma of the head and neck (SCCHN) patients in a Phase 2 basket trial combining IO102-IO103 with pembrolizumab.

The poster, titled 'A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)', will be presented on September 14, 2024, at the congress in Barcelona. This data represents a significant step in exploring IO102-IO103's potential across various solid tumors with high unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
Rhea-AI Summary

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, announced its participation at the Jefferies Global Healthcare Conference, occurring from June 4-6, 2024, in New York, NY.

The company's President and CEO, Mai-Britt Zocca, Ph.D., will present on June 5, 2024, from 7:30-7:55 AM EST, discussing IO Biotech’s development of novel cancer vaccines using their T-win® platform.

Additionally, both Dr. Zocca and CFO Amy Sullivan will engage in one-on-one meetings with investors during the conference. A webcast of the presentation will be available on the company's website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary

IO Biotech has reported its financial results for Q1 2024, highlighting a net loss of $19.5 million, up from $17.0 million in Q1 2023. Research and development expenses increased to $14.3 million, attributed to clinical trial activities for its cancer vaccine candidate, IO102-IO103. General and administrative expenses slightly decreased to $5.9 million. The company ended the quarter with $118 million in cash, down from $143.2 million in December 2023.

Key developments include the completion of patient enrollment in the pivotal Phase 3 trial of IO102-IO103 in combination with pembrolizumab for advanced melanoma. The interim analysis for the overall response rate (ORR) is expected in Q3 2024, and the primary endpoint of progression-free survival (PFS) in H1 2025. Additionally, Phase 2 trials IOB-022 and IOB-032 have progressed, with significant enrollment milestones achieved. The executive team has been strengthened with new hires to enhance business and commercial development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
IO Biotech announces that its abstract related to IO102-IO103, the lead investigational therapeutic cancer vaccine candidate, has been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting. The abstract focuses on the Phase 2 trial combining IO102-IO103 with Merck's KEYTRUDA for melanoma and head and neck cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
Rhea-AI Summary
IO Biotech appoints Marjan Shamsaei as SVP, Commercial Development, and Portfolio Lead to advance commercialization readiness for IO102-IO103 cancer vaccine candidate in Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
management

FAQ

What is the current stock price of IO Biotech (IOBT)?

The current stock price of IO Biotech (IOBT) is $1.15 as of October 4, 2024.

What is the market cap of IO Biotech (IOBT)?

The market cap of IO Biotech (IOBT) is approximately 66.5M.

What does IO Biotech, Inc. do?

IO Biotech, Inc. develops innovative immune therapies for the treatment of cancer, focusing on immune-modulating anti-cancer therapies.

What are IO Biotech's leading therapies?

Their leading therapies target IDO and PD-L1, both currently in clinical development.

What technology platform does IO Biotech use?

They use the T-win technology platform, which aims to induce the immune system to disrupt multiple pathways regulating tumor-induced immunosuppression.

What is the company's track record in advancing therapies?

IO Biotech has a proven track record of progressing compounds to the clinical stage.

Who is part of IO Biotech's team?

They have an experienced management team in immuno-oncology and a world-class advisory board.

What recent achievements has IO Biotech made?

Recent achievements include the advancement of pivotal Phase 3 Clinical Trials and progress with drugs IO102 and IO103.

How can I get the latest updates on IO Biotech?

You can visit their official website or contact their Director of Investor Relations, Maryann Cimino, at mci@iobiotech.com.

What is the focus of IO Biotech's research?

Their research focuses on developing first-in-class immune-modulating cancer vaccines.

What is unique about IO Biotech's approach to cancer treatment?

Their unique approach involves activating T cells to specifically target immune inhibitory molecules, enhancing the body's ability to fight cancer.

How can I contact IO Biotech for more information?

You can contact Maryann Cimino, Director of Investor Relations, at 617-710-7305 or via email at mci@iobiotech.com.

IO Biotech, Inc.

Nasdaq:IOBT

IOBT Rankings

IOBT Stock Data

66.54M
65.88M
0.24%
77.3%
0.07%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
COPENHAGEN